Pediatric trials network
This presentation is the property of its rightful owner.
Sponsored Links
1 / 13

Pediatric Trials Network PowerPoint PPT Presentation


  • 59 Views
  • Uploaded on
  • Presentation posted in: General

Pediatric Trials Network. March 27, 2014. A project of the Best Pharmaceuticals for Children Act. Why are studies in children difficult?. Limited number of patients with the disease No “healthy child/baby volunteer” Low rates of parental informed consent Perceived study risks

Download Presentation

Pediatric Trials Network

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Pediatric trials network

Pediatric Trials Network

March 27, 2014

A project of the Best Pharmaceuticals for Children Act


Why are studies in children difficult

Why are studies in children difficult?

  • Limited number of patients with the disease

  • No “healthy child/baby volunteer”

  • Low rates of parental informed consent

  • Perceived study risks

  • Limited blood volume and timed sampling

  • Sick population – increases variability

  • Lack of clinical pharmacology expertise

  • Lack of pediatric PK/PD modeling expertise


How did the ptn start

How Did The PTN Start?

“Create an infrastructure for investigators to conduct trials that improve pediatric labeling and child health.”

  • Sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  • Network for studying drug product formulation, age-appropriate drug dosing, efficacy, safety, and device validation

  • Success: Completed trials that improve dosing, safety information, labeling, and ultimately child health


Pediatric trials network1

Pediatric Trials Network

  • PI: Benjamin

  • Since 2010, ~25 ongoing projects, 12 clinical trials

  • Phase 1 and 2 studies

  • All therapeutic areas

  • 5 CSRs submitted to FDA

  • 4-6 potential label changes

  • Training of fellows/junior faculty


Ptn structure

PTN Structure


Ptn administrative core

PTN Administrative Core


Ptn fellows

PTN Fellows


Pediatric trials network2

Pediatric Trials Network


Ptn site participation

PTN Site Participation

  • 255 investigators at 138 sites expressed interest in participating

  • Anticipate ~60 sites actively enrolling in trials conducted in 2014

  • Growth of the “rapid start network”, a pediatric clinical trial consortium affiliated with PTN to a total of approximately 100 sites


Ptn update

PTN Update

  • Metronidazole: 3 sites, 24 premature infants at risk for NEC. Protocol chair: Michael Cohen-Wolkowiez. Enrollment and analysis complete, CSR submitted to FDA, published in PIDJ

  • Acyclovir: 3 sites, 32 preterm and term infants with suspected HSV. Protocol chair: Brian Smith. Enrollment and analysis complete, CSR submitted to FDA, published in PIDJ

  • TAPE weight estimate device: 3 sites, 625 children. Protocol chair: Sue Rahman, Children’s Mercy Hospital, Kansas City, MO. Enrollment and analysis complete. CSR submitted to FDA, published Ann of Emer Med

  • Hydroxyurea: 6 sites, 40 children. Protocol chair: Kathleen Neville, Children’s Mercy Hospital, Kansas City, MO. Enrollment and analysis complete. CSR submitted to FDA

  • Opportunistic (POPS I and POPD II):36sites, 1200 children. Protocol chair: Michael Cohen-Wolkowiez. Enrollment ongoing (>1000 enrolled to date)

  • Lisinopril PK: 8 sites, 24 children with kidney transplants and HTN. Protocol chair: Howard Trachtman, NYU Langone Medical Center. Enrollment complete. Analysis ongoing


Ptn update1

PTN Update

  • Midazolam meta-analysis: Support change of current midazolam labeling to include the treatment of seizures in children ages 2 years and older using existing PK and safety data. Protocol chair: Brian Smith. Analysis in progress.

  • Ampicillin meta-analysis: PK analysis in combination with 2 retrospective cohort studies of infants with sepsis and/or meningitis. 1 site, 64 infants. Protocol chair: Michael Cohen-Wolkowiez. Data collection and analysis complete, CSR submitted to FDA. PAS poster.

  • Obesity informatics: Literature search to create a database with published PK studies for the NIH Priority Drug List relevant to pediatric obesity. Protocol chair: Kevin Watt. Literature review complete. PAS poster.

  • Staph microtrials: 9 sites, 96 infants, 3 anti-staph drugs. Protocol chair: Matt Laughon, UNC. Enrollment ongoing.

  • Sildenafil: 5 sites, up to 24 infants with pulmonary arterial hypertension or lung disease. Protocol chair: Matt Laughon, UNC. Enrollment ongoing.

  • Clindamycin obesity: 6 sites, up to 32 children. Safety/PK study of multiple-dose IV and oral clindamycin in obese children. Protocol chair: Janice Sullivan, University of Louisville, KY. Enrollment ongoing. Federated IRB.


Ptn update2

PTN Update

  • Methadone PICU: 4 sites, up to 36 patients. Protocol chair: Kevin Watt. Enrollment ongoing.

  • Diuretics in NICU: retrospective review: 2 sites, 700 pts. Protocol Chair: Matt Laughon, UNC. Data collection ongoing.

  • Piperacillin-tazobactam, clindamycin, metronidazole, ampicillin safety in infants with complicated intraabdominal infections (SCAMP): 50 sites, 374 subjects, Protocol Chair: Michael Cohen-Wolkowiez. Site start up

  • Pantoprazole obesity: 3 sites and 60 children. Study to determine effect of obesity on the PK/PD of pantoprazole in children. Protocol chair: Greg Kearns, Children’s Mercy Hospital, Kansas City, MO. Site start up.

  • Pediatrix meta-analysis of safety of 11 drugs: Retrospective data analysis; database to include >300 sites and >800,000 infants and data from FDA. Protocol chair: Brian Smith. Data analysis.

  • Fluconazole safety meta-analysis: 33 sites, 361 infants enrolled in an earlier RCT. Protocol chair: Brian Smith. Data analysis.


Ptn resources

PTN Resources

  • How to get involved:

    https://pediatrictrials.org/how-to-get-involved

  • How to develop a concept sheet:

    https://pediatrictrials.org/how-to-get-involved/for-healthcare-professionals


  • Login